| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2018: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2016: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary arterial hypertension (PAH) is a severe disease which causes stenosis and occlusion in the pulmonary small arteries and arterioles, leading to elevation of pulmonary arterial pressure due to unknown etiology. Since PAH patients might eventually result in right heart failure and death without adequate treatment, PAH is designated as an intractable disease by MHLW.We need to develop a novel therapeutic strategy for PAH which is distinct from the anti-PAH vaso-dilating agents. We identified IL-21 as a downstream target of IL-6 responsible for promoting the pathogenesis of HPH(PNAS.112: E2677, 2015).In this study, we tried to validate the effect of either IL-6 blockade or IL-21 blockade on the pathogenesis of PAH in a more severe animal model, namely the Sugen5416(Su)/Hypoxia/Normoxia (Su/Hx) rat model. We found that both IL-6 knockout and IL-21 receptor knockout rats showed significant resistance to severe PAH compared with conrol wild-type rats.
|
